HUTCHMED (China) Ltd
fanregratinib
intrahepatic cholangiocarcinoma
Resolved
3days ago
Phase 2 readout · Jul 4, 2026
What's at stake
Phase 2 trial results for fanregratinib in intrahepatic cholangiocarcinoma are due Jul 4, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 13h ago
“results from the pivotal Phase II registration study of fanregratinib (HMPL-453) in patients with intrahepatic cholangiocarcinoma (“ICC”) will be presented at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congres”